Viral infections in immunocompromised patients.
D000212:Acyclovir / Q000627:therapeutic use; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D002051:Burkitt Lymphoma / Q000209:etiology; D002644:Chickenpox / Q000209:etiology; D002648:Child; D003586:Cytomegalovirus Infections / Q000209:etiology; D004198:Disease Susceptibility; D004769:Enterovirus Infections / Q000209:etiology; D006561:Herpes Simplex / Q000209:etiology; D006562:Herpes Zoster / Q000209:etiology; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000150:complications*; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007244:Infectious Mononucleosis / Q000209:etiology; D009976:Orthomyxoviridae Infections / Q000209:etiology; D010253:Respirovirus Infections / Q000209:etiology; D014740:Vidarabine / Q000627:therapeutic use; D014777:Virus Diseases / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy
D000998:Antiviral Agents; D014740:Vidarabine; D000212:Acyclovir